Neurocrine Biosciences (NBIX) Insider Trading & Ownership $146.76 +0.88 (+0.60%) As of 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Neurocrine Biosciences (NASDAQ:NBIX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.30%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)17Amount OfInsider Selling(Last 12 Months)$56.89 M Get NBIX Insider Trade Alerts Want to know when executives and insiders are buying or selling Neurocrine Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NBIX Insider Buying and Selling by Quarter Neurocrine Biosciences Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/15/2025Kyle GanoCEOSell65,000$141.50$9,197,500.00 12/31/2024Ingrid DelaetInsiderSell272$138.10$37,563.20 12/17/2024Ingrid DelaetInsiderSell1,091$135.00$147,285.00 11/29/2024Jude OnyiaInsiderSell2,331$126.29$294,381.99 8/15/2024William H RastetterDirectorSell14,250$146.69$2,090,332.50 8/13/2024Gary A LyonsDirectorSell11,570$150.43$1,740,475.10 8/13/2024Ingrid DelaetInsiderSell7,143$150.10$1,072,164.30 8/13/2024Matt AbernethyCFOSell14,100$150.38$2,120,358.00 8/6/2024Ingrid DelaetInsiderSell273$147.70$40,322.10 8/1/2024Julie CookeInsiderSell12,632$153.26$1,935,980.32 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 7/16/2024Gary A LyonsDirectorSell930$150.03$139,527.90 7/16/2024Julie CookeInsiderSell900$150.04$135,036.00 7/1/2024Julie CookeInsiderSell10,000$140.19$1,401,900.00 5/29/2024Stephen A SherwinDirectorSell40,000$133.46$5,338,400.00 5/17/2024Shalini SharpDirectorSell1,106$141.90$156,941.40 5/15/2024Matt AbernethyCFOSell15,000$140.24$2,103,600.00 5/14/2024Gary A LyonsDirectorSell12,500$135.63$1,695,375.00 5/6/2024Ingrid DelaetInsiderSell273$140.55$38,370.15 4/15/2024Eric BenevichInsiderSell19,818$133.36$2,642,928.48 3/21/2024Ingrid DelaetInsiderSell5,000$145.06$725,300.00 3/14/2024Eric BenevichInsiderSell75,000$139.38$10,453,500.00 3/14/2024George J. MorrowDirectorSell40,000$139.42$5,576,800.00 3/11/2024Ingrid DelaetInsiderSell200$140.00$28,000.00 3/11/2024Richard F PopsDirectorSell100$140.00$14,000.00 3/8/2024Ingrid DelaetInsiderSell1,800$140.03$252,054.00 3/8/2024Richard F PopsDirectorSell1,700$140.05$238,085.00 2/29/2024Ingrid DelaetInsiderSell273$135.51$36,994.23 2/27/2024Leslie V. NorwalkDirectorSell8,000$135.67$1,085,360.00 2/20/2024Richard F PopsDirectorSell15,000$132.47$1,987,050.00 2/13/2024Eiry RobertsInsiderSell1,114$132.96$148,117.44 2/13/2024Kevin Charles GormanCEOSell2,832$133.02$376,712.64 2/13/2024Matt AbernethyCFOSell1,352$132.85$179,613.20 2/8/2024David W BoyerInsiderSell1,328$135.41$179,824.48 2/8/2024Kevin Charles GormanCEOSell2,274$134.15$305,057.10 2/8/2024Matt AbernethyCFOSell980$134.21$131,525.80 2/6/2024David W BoyerInsiderSell456$141.96$64,733.76 2/6/2024Kevin Charles GormanCEOSell3,040$142.18$432,227.20 2/6/2024Matt AbernethyCFOSell1,280$142.19$182,003.20 1/31/2024Eiry RobertsInsiderSell1,457$140.79$205,131.03 1/31/2024Kevin Charles GormanCEOSell2,707$140.69$380,847.83 "Elon Musk’s Final Move”: Get in NOW (Ad)I believe Elon's next venture, his "Final Move," could mint more millionaires than any project he's ever been a part of before.Click Here to see why - and get all the details on how you could join him >>>1/31/2024Matt AbernethyCFOSell1,283$140.72$180,543.76 1/22/2024Darin LippoldtInsiderSell10,000$139.86$1,398,600.00 (Data available from 1/1/2013 forward) NBIX Insider Trading Activity - Frequently Asked Questions Who is on Neurocrine Biosciences's Insider Roster? The list of insiders at Neurocrine Biosciences includes Darin Lippoldt, David W Boyer, Eiry Roberts, Eric Benevich, Gary A Lyons, George J. Morrow, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Leslie V. Norwalk, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Shalini Sharp, Stephen A Sherwin, and William H Rastetter. Learn more on insiders at NBIX. What percentage of Neurocrine Biosciences stock is owned by insiders? 4.30% of Neurocrine Biosciences stock is owned by insiders. Learn more on NBIX's insider holdings. Which Neurocrine Biosciences insiders have been buying company stock? The following insider purchased NBIX shares in the last 24 months: Neurocrine Biosciences Inc ($39,032,821.44). How much insider buying is happening at Neurocrine Biosciences? Insiders have purchased a total of 4,395,588 NBIX shares in the last 24 months for a total of $39,032,821.44 bought. Which Neurocrine Biosciences insiders have been selling company stock? The following insiders have sold NBIX shares in the last 24 months: Darin Lippoldt ($5,121,159.93), David W Boyer ($700,550.20), Eiry Roberts ($4,982,223.40), Eric Benevich ($13,333,672.48), Gary A Lyons ($5,284,628.00), George J. Morrow ($5,576,800.00), Ingrid Delaet ($2,531,914.10), Jude Onyia ($902,482.92), Julie Cooke ($4,748,356.97), Kevin Charles Gorman ($17,369,891.33), Kyle Gano ($19,057,750.00), Leslie V. Norwalk ($1,085,360.00), Matt Abernethy ($7,963,690.98), Richard F Pops ($2,239,135.00), Shalini Sharp ($156,941.40), Stephen A Sherwin ($5,338,400.00), and William H Rastetter ($4,707,062.54). How much insider selling is happening at Neurocrine Biosciences? Insiders have sold a total of 769,015 Neurocrine Biosciences shares in the last 24 months for a total of $101,100,019.25 sold. Neurocrine Biosciences Key ExecutivesDr. Kevin C. Gorman Ph.D. (Age 66)CEO & Director Compensation: $2.05MMr. Matthew C. Abernethy (Age 44)Chief Financial Officer Compensation: $1.06MDr. Jude Onyia Ph.D. (Age 60)Chief Scientific Officer Compensation: $1.22MMr. Kyle W. Gano Ph.D. (Age 51)Chief Business Development & Strategy Officer Compensation: $990.12kDr. Eiry Wyn Roberts M.D. (Age 60)Chief Medical Officer Compensation: $1.12MJane SorensenHead of Investor RelationsMr. Darin M. Lippoldt Esq. (Age 58)Chief Legal Officer & Corporate Secretary Compensation: $921.01kMs. Julie S. Cooke (Age 58)Chief Human Resources Officer 1 recent tradesMr. Eric S. Benevich (Age 59)Chief Commercial Officer Compensation: $805kMr. David Warren Boyer (Age 44)Chief Corporate Affairs Officer More Insider Trading Tools from MarketBeat Related Companies Alnylam Pharmaceuticals Insider Buying Biogen Insider Buying United Therapeutics Insider Buying Incyte Insider Buying BioMarin Pharmaceutical Insider Buying Exelixis Insider Buying Exact Sciences Insider Buying Repligen Insider Buying Halozyme Therapeutics Insider Buying Madrigal Pharmaceuticals Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (NASDAQ:NBIX) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredThe Stock I’m Calling My #1 of the DecadeThe stock I reveal right here is my #1 stock of the decade. In fact, it might be my favorite stock ever. ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
